DOI QR코드

DOI QR Code

Talin-1 Correlates with Reduced Invasion and Migration in Human Hepatocellular Carcinoma Cells

  • Fang, Kun-Peng (First Affiliated Hospital of Anhui Medical University) ;
  • Zhang, Jian-Lin (First Affiliated Hospital of Anhui Medical University) ;
  • Ren, Yan-Hong (First Affiliated Hospital of Anhui Medical University) ;
  • Qian, Ye-Ben (First Affiliated Hospital of Anhui Medical University)
  • Published : 2014.03.30

Abstract

Background: Talin-1 is a cytoskeleton protein that participates in cell migration and plays a role in tumor formation, migration, and metastasis in different types of cancer. Chinese investigators have observed that the levels of Talin-1 protein and mRNA expression in HCC tissues are significantly lower than in the adjacent non-cancerous tissue. However, Japanese investigators have reported that Talin-1 is upregulated in HCC. Tln2 as homologous gene of Tln-1, which encodes a very similar protein, but the role of Talin-2 is very little known in primary liver cancer (PLC). We investigated whether the expression of Talin-1 in PLC may be associated with the histological subtype as well as the role of Talin-1 in tumor cell invasion and migration using human hepatocellular carcinoma cell lines. Materials and Methods: We measured the mRNA expression levels of Talin-1 and Talin-2 in five human liver cancer cell lines and normal human liver cell ($LO_2$ cell line) by real-time PCR and the protein expression levels of Talin-1 by Western blot. Migration and invasion of the cells were assessed using transwell assays and cell scratch experiments, respectively, and proliferation was assessed by soft AGAR colony formation. Results: Talin-1 and Talin-2 expression differed significantly between the five human liver cancer cell lines and $LO_2$ cell line (p<0.05). Compared with the $LO_2$ cell line, the invasion and migration capabilities of the five cancer cell lines differed significantly (p<0.05). Similarly, the colony-forming ability differed (p<0.05). Conclusions: High levels of Talin-1 expression are correlated with reduced invasion and migration as well as decreased malignancy in human liver cancer cell lines; the suppression of Talin-1 promotes invasion and migration. In addition, Talin-2 may be correlated with invasion and migration in human hepatocellular carcinoma.

Keywords

Hepatocellular carcinoma;HCC;Talin-1;Talin-2;migration;invasion;cell lines

References

  1. Youns MM, Abdel Wahab AH, Hassan ZA, et al (2013). Serum talin-1 is a potential novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Asian Pac J Cancer Prev, 14, 3819-23. https://doi.org/10.7314/APJCP.2013.14.6.3819
  2. Zavaglia C, De Carlis L, Alberti AB, et al (2005). Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol, 100, 2708-16. https://doi.org/10.1111/j.1572-0241.2005.00289.x
  3. Tian J, Tang ZY, Ye SL, et al (1999). New human hepatocellular carcinoma(HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer, 81, 814-21. https://doi.org/10.1038/sj.bjc.6690769
  4. Wang Z, Ruan YB, Guan Y, et al (2003). Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol, 9, 267-70.
  5. Zender L, Spector MS, Xue W, et al (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 125, 1253-67. https://doi.org/10.1016/j.cell.2006.05.030
  6. Zhang X, Jiang G, Cai Y, et al (2008). Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol, 10, 1062-8. https://doi.org/10.1038/ncb1765
  7. Zhang JL, Qian YB, Xiong QR, et al (2011). Talin1, a valuable marker for diagnosis and prognostic assessment of human hepatocelluar carcinomas. Asian Pac J Cancer Prev, 12, 3265-9.
  8. Sakamoto S, McCann RO, Kyprianou N, et al (2010). Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res, 70, 1885-95. https://doi.org/10.1158/0008-5472.CAN-09-2833
  9. Senetar MA, McCann RO (2005). Gene duplication and functional divergence during evolution of the cytoskeletal linker protein talin. Gene, 362, 141-52. https://doi.org/10.1016/j.gene.2005.08.012
  10. Senetar MA, Moncman CL, McCann RO (2007). Talin2 is induced during striated muscle differentiation and is targeted to stable adhesion complexes in mature muscle. Cell Motil Cytoskeleton, 64, 157-73 https://doi.org/10.1002/cm.20173
  11. Slater M, Cooper M, Murphy CR (2007). The cytoskeletal proteins alpha-actinin, Ezrin, and talin are de-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium. Appl Immunohistochem Mol Morphol, 15, 170-4. https://doi.org/10.1097/01.pai.0000194762.78889.26
  12. Shafizadeh N, Kakar S (2013). Hepatocellular carcinoma: Histologic subtypes. Surgical Pathology Clinics, 6, 367-84. https://doi.org/10.1016/j.path.2013.03.007
  13. Singel SM, Cornelius C, Batten K, et al (2013). A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res, 19, 2061-70 https://doi.org/10.1158/1078-0432.CCR-13-0082
  14. Sriputtha S, Khuntikeo N, Promthet S, et al (2013). Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac J Cancer Prev, 14, 1107-10. https://doi.org/10.7314/APJCP.2013.14.2.1107
  15. Takayama T, Makuuchi M, Hirohashi S, et al (1990). Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet, 336, 1150-3. https://doi.org/10.1016/0140-6736(90)92768-D
  16. Takayama T, Makuuchi M, Hirohashi S, et al (1998). Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology, 28, 1241-6. https://doi.org/10.1002/hep.510280511
  17. Lai MT, Hua CH, Tsai MH, et al (2011). Talin-1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis. J Pathol, 224, 367-76 https://doi.org/10.1002/path.2867
  18. Li MS, Li PF, He SP, et al (2002). The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel-7402 cell line. World J Gastroenterol, 8, 469-75.
  19. Lou CY, Feng YM, Qian AR, et al (2004). Establishment and characterization of a human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol, 10, 1462-5.
  20. Laurent-Puig P, Zucman-Rossi J (2006). Genetics of hepatocellular tumors. Oncogene, 25, 3778-86. https://doi.org/10.1038/sj.onc.1209547
  21. Morris KM, Aden DP, Knowles BB, et al (1982). Complement biosynthesis by the human hepatoma-derived cell line HePG2. J Clin Invest, 70, 906-13. https://doi.org/10.1172/JCI110687
  22. Monkley SJ, Pritchard CA, Critchley DR (2001). Analysis of the mammalian talin2 gene TLN2. Biochem Biophys Res Commun, 286, 880-5. https://doi.org/10.1006/bbrc.2001.5497
  23. Monkley SJ, Kostourou V, Spence L, et al (2011). Endothelial cell talin1 is essential for embryonic angiogenesis. Dev Biol, 349, 494-502. https://doi.org/10.1016/j.ydbio.2010.11.010
  24. Praekelt U, Kopp PM, Rehm K, et al (2012). New isoformspecific monoclonal antibodies reveal different sub-cellular localisations for talin1 and talin2. Eur J Cell Biol, 91, 180-91 https://doi.org/10.1016/j.ejcb.2011.12.003
  25. Roayaie S, Schwartz JD, Sung MW, et al (2004). Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl, 10, 534-40. https://doi.org/10.1002/lt.20128
  26. Schafer DF, Sorrell MF (1999). Hepatocellular carcinoma. Lancet, 353, 1253-7. https://doi.org/10.1016/S0140-6736(98)09148-X
  27. Song ZQ, Hao F, Min F, et al (2001). Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. World J Gastroenterol, 7, 685-9.
  28. Kopp PM, Bate N, Hansen TM, et al (2010). Studies on the morphology and spreading of human endothelial cells define key inter- and intramolecular interactions for talin1. Eur J Cell Biol, 89, 661-73 https://doi.org/10.1016/j.ejcb.2010.05.003
  29. International Consensus Group for Hepatocellular Neoplasia(2009). Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 49, 658-64. https://doi.org/10.1002/hep.22709
  30. Kakar S, Burgart LJ, Batts KP, et al (2005). Clinicopathologic features and survival in fibrolamellar carcinoma: Comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol, 18, 1417-23. https://doi.org/10.1038/modpathol.3800449
  31. Kirk GD, Bah E, Montesano R (2006). Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis, 27, 2070-82 https://doi.org/10.1093/carcin/bgl060
  32. Kanamori H, Kawakami T, Effendi K, et al (2011). Identification by differential tissue proteome analysis of Talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology, 80, 406-15 https://doi.org/10.1159/000330734
  33. Lack EE, Neave C, Vawter GF (1983). Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer, 52, 1510-5 https://doi.org/10.1002/1097-0142(19831015)52:8<1510::AID-CNCR2820520830>3.0.CO;2-7
  34. Lauwers GY, Terris B, Balis UJ, et al (2002). International Cooperative Study Group on Hepatocellular Carcinoma. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: A multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol, 26, 25-34. https://doi.org/10.1097/00000478-200201000-00003
  35. Li Y, Tang ZY, Ye SL, et al (2001). Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol, 7, 630-6.
  36. Debrand E, Conti FJ, Bate N, et al (2012). Mice carrying a complete deletion of the talin2 coding sequence are viable and fertile. Biochem Bioph Res Co, 426, 190-5 https://doi.org/10.1016/j.bbrc.2012.08.061
  37. Conti FJ, Felder A, Monkley S, et al (2008). Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. Development, 135, 2043-53 https://doi.org/10.1242/dev.015818
  38. Conti FJ, Monkley SJ, Wood MR, et al (2009). Talin 1 and 2 are required for myoblast fusion, sarcomere assembly and the maintenance of myotendinous junctions. Development, 136, 3597-606 https://doi.org/10.1242/dev.035857
  39. Debrand E, El Jai Y, Spence L, et al (2009). Talin 2 is a large and complex gene encoding multiple transcripts and protein isoforms. FEBS J, 276, 1610-28 https://doi.org/10.1111/j.1742-4658.2009.06893.x
  40. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76 https://doi.org/10.1053/j.gastro.2007.04.061
  41. Fazeli Z, Pourhoseingholi MA, Vahedi M, et al (2012). Burden of hepatocellular carcinoma in Asia. Asian Pac J Cancer Prev, 13, 5955-8. https://doi.org/10.7314/APJCP.2012.13.12.5955
  42. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87 https://doi.org/10.1038/nrc1934
  43. Fornaro M, Manes T, Languino LR (2001). Integrins and prostate cancer metastases. Cancer Metastasis Rev, 20, 321-31 https://doi.org/10.1023/A:1015547830323
  44. Giancotti FG, Ruoslahti E (1999). Integrin signaling. Science, 285, 1028-32 https://doi.org/10.1126/science.285.5430.1028
  45. Hodgson HJ (1987). Fibrolamellar cancer of the liver. J Hepatol, 5, 241-7 https://doi.org/10.1016/S0168-8278(87)80580-9
  46. Hui KM (2009). Human hepatocellular carcinoma: Expression profiles-based molecular interpretations and clinical applications. Cancer Lett, 286, 96-102 https://doi.org/10.1016/j.canlet.2008.11.005
  47. Ishak KG, Goodman ZD, Stocker JT (2001). Tumors of the liver and intrahepatic bile ducts. Washington, DC: Armed Forces Institute of Pathology
  48. Anthis NJ, Wegener KL, Critchley DR, et al (2010). Structural diversity in integrin/talin interactions. Structure, 18, 1654-66. https://doi.org/10.1016/j.str.2010.09.018
  49. Beer DG, Kardia SL, Huang CC, et al (2002). Geneexpression profiles predict survival of patients with lung adenocarcinoma. Nat Med, 8, 816-24.
  50. Craig JR, Peters RL, Edmondson HA, et al (1980). Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer, 46, 372-9. https://doi.org/10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S
  51. Calderwood DA (2004). Integrin activation. J Cell Sci, 117, 657-66. https://doi.org/10.1242/jcs.01014
  52. Critchley DR (2004). Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. Biochem Soc Trans, 32, 831-6 https://doi.org/10.1042/BST0320831

Cited by

  1. Both Talin-1 and Talin-2 correlate with malignancy potential of the human hepatocellular carcinoma MHCC-97 L cell vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2076-9
  2. Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway vol.108, pp.6, 2017, https://doi.org/10.1111/cas.13247
  3. cells vol.40, pp.4, 2017, https://doi.org/10.1080/01480545.2016.1264411
  4. Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6333
  5. Breaking down Leukemia Walls: Heteronemin, a Sesterterpene Derivative, Induces Apoptosis in Leukemia Molt4 Cells through Oxidative Stress, Mitochondrial Dysfunction and Induction of Talin Expression vol.16, pp.6, 2018, https://doi.org/10.3390/md16060212